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Abstract
Background and Objective: Postoperative cardiocerebral and renal complications are a major threat for patients
undergoing cardiac surgery. This study was aimed to examine the effect of preoperative aspirin use on patients undergoing
cardiac surgery.
Methods: An observational cohort study was performed on consecutive patients (n=1879) receiving cardiac surgery at this
institution. The patients excluded from the study were those with preoperative anticoagulants, unknown aspirin use, or
underwent emergent cardiac surgery. Outcome events included were 30-day mortality, renal failure, readmission and a
composite outcome - major adverse cardiocerebral events (MACE) that include permanent or transient stroke, coma,
perioperative myocardial infarction (MI), heart block and cardiac arrest.
Results: Of all patients, 1145 patients met the inclusion criteria and were divided into two groups: those taking (n=858) or
not taking (n=287) aspirin within 5 days preceding surgery. Patients with aspirin presented significantly more with history
of hypertension, diabetes, peripheral arterial disease, previous MI, angina and older age. With propensity scores adjusted
and multivariate logistic regression, however, this study showed that preoperative aspirin therapy (vs. no aspirin)
significantly reduced the risk of MACE (8.4% vs. 12.5%, odds ratio [OR] 0.585, 95% CI 0.355–0.964, P=0.035), postoperative
renal failure (2.6% vs. 5.2%, OR 0.438, CI 0.203–0.945, P=0.035) and dialysis required (0.8% vs. 3.1%, OR 0.230, CI 0.071–
0.742, P=0.014), but did not significantly reduce 30-day mortality (4.1% vs. 5.8%, OR 0.744, CI 0.376–1.472, P=0.396) nor it
increased readmissions in the patients undergoing cardiac surgery.
Conclusions: Preoperative aspirin therapy is associated with a significant decrease in the risk of MACE and renal failure and
did not increase readmissions in patients undergoing non-emergent cardiac surgery.
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Introduction
Although tremendous progress has been made in the field of
cardiac surgery over the past four decades, major cerebral, cardiac
and renal complications associated with cardiac surgery remain
common and significant [1]–[3]. According to the Society of
Thoracic Surgeons (STS) data reports (2009), the 30-day operative
death and major complication rates for valve plus coronary artery
bypass graft (CABG) procedure were 6.8% and 30.1%, respec-
tively, including stroke (2.9%), renal failure (9.0%), reoperation
(11.9%), prolonged ventilation (21.2%), and sternal infection
(0.7%) [3].
Importantly, there is still lacking of an effective clinical therapy
to prevent these major cardiocerebral and renal complications.
Nonetheless, aspirin as an antiplatelet and antiinflammatory agent
has been one of major medicines in prevention and treatment of
cardiovascular disease (CVD). Accumulating evidence has dem-
onstrated that aspirin significantly reduces all-cause mortality, MI
and stroke in patients with risk of CVD [4]–[7]. Meanwhile, early
postoperative aspirin therapy has been applied to improve
postoperative outcomes in patients undergoing CABG, including
improved graft patency, a reduced risk of death and ischemic
complications [8]–[13]. However, it remains to be determined
about whether preoperative aspirin therapy can reduce major
adverse cardiocerebral (MACE) and renal events in patients
undergoing cardiac surgery [14]–[16].
Based on the finding of aspirin’s overall beneficial effects in
patients with CVD from previous large clinical trials and meta-
analysis [4–7], we hypothesized that preoperative use of aspirin,
mainly through its antiinflammatory and antithrombotic effects,
would provide cardiovascular protection against major cardiocer-
ebral and renal complications in patients undergoing cardiac
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30094surgery. Thus, the present study aimed to test the overall effects of
preoperative aspirin use on cardiocerebral and renal outcomes in
patients undergoing non-emergent cardiac surgery.
Methods
Study Design
This study was an observational cohort study involving consec-
utive patients (n=1879) receiving cardiac surgery (84% patients
werefor CABGor/and valve surgery) at thisuniversity hospital from
August 2003 to December 2009. The study was in compliance with
Declaration of Helsinki and reviewed and approved by Thomas
Jefferson University Institutional Review Board, and individual
consent was waived in compliance with the HIPAA regulations and
the waiver criteria. The patients excluded from the study were those
with preoperative anticoagulants, unknown aspirin use, or under-
went emergent cardiac surgery, i.e., the patient’s clinical status
includes any of the following: ischemic dysfunction, mechanical
dysfunction (such as acute evolving MI or shock with circulatory
support) or emergent salvage (see details at: http://www.sts.org/
documents/pdf/trainingmanuals/Tab9-SectionIOPERATIVE.pdf.
[accessed at July 9, 2010]). Of all patients, 1145 patients met the
inclusion criteria and were divided into two groups: using (n=858)
or not using (n=287) preoperative (within 5 days preceding surgery)
aspirin (Fig. 1).
Data Collection
The patient data were collected and organized to follow the
template of the STS national database, including demographics,
patient history, medical record information, preoperative risk
factors, preoperative medications, intraoperative data, postopera-
tive MACE, renal failure and 30-day all cause mortality.
Independent investigators prospectively collected the data on each
patient during the course of hospitalization for cardiac surgery.
Missing data values for dichotomous variables were assigned the
most frequent value, while continuous variables were assigned the
median value, except for body surface area, which was assigned
the sex-specific median value [17]. Preoperative use of aspirin
indicates use of aspirin in the patient within 5 days preceding
surgery.
MACE included permanent or transient stroke, coma, periop-
erative MI, heart block and cardiac arrest. Based on the STS
national criteria, permanent stroke is defined as a new-onset
cerebrovascular accident persisting .24 h; transient stroke as a
transient episode of neurological dysfunction caused by focal
brain, spinal cord, or retinal ischemia, without acute infarction;
coma, the patient had a new postoperative coma that persists for at
least 24 hrs secondary to anoxic/ischemic and or/metabolic
encephalopathy, thromboembolic event or cerebral bleed; peri-
operative MI as patient as documented by the following criteria
(,24 hours post-op): The CK-MB (or CK if MB not available)
must be greater than or equal to 5 times the upper limit of normal,
with or without new Q waves present in two or more contiguous
ECG leads, no symptoms required; or as documented by at least
one of the following criteria (.24 hours post-op): 1) Evolutionary
ST- segment elevations, 2) Development of new Q- waves in two
or more contiguous ECG leads, 3) New or presumably new LBBB
pattern on the ECG, 4) The CK-MB (or CK if MB not available)
must be greater than or equal to 3 times the upper limit of normal;
heart block as a new heart block requiring the implantation of a
permanent pacemaker of any type prior to discharge; postoper-
ative renal failure as acute or worsening renal failure resulting in
one or more of the followings: increase in serum creatinine
.2.0 mg/dL and 26 most recent preoperative creatinine level
over baseline or new requirement for dialysis postoperatively; and
readmission as the patient was readmitted as an in-patient within
30-days from the date of initial surgery for any reason. This
includes readmissions to acute care, primary care institutions only,
not to rehabilitation hospital or nursing home. The remaining
definitions are available at http://www.sts.org/documents/pdf/
trainingmanuals/adult2.61/V-c-AdultCVDataSpecifications2.61.
pdf (accessed at July 27, 2010).
Statistical Analysis
Continuous and categorical variables were reported as mean 6
SD or percentages, and compared with a 2-sample t tests or a chi-
square test (two tailed), respectively. Univariate and multivariate
logistic regression were performed to assess associations of
demographic, therapeutic and clinical outcome variables.
As described previously [18], because this was an observational
study, a propensity score-adjusted analysis was performed to
control for selection bias as result of nonrandom assignment to the
two groups. A propensity score was derived, reflecting the
probability that a patient would receive preoperative aspirin. This
was accomplished by performing a multivariable logistic regression
analysis using preoperative aspirin as the dependent variable and
entering all baseline (preoperative) variables as in table 1 that
clinically would likely affect the probability of using preoperative
aspirin.
In this study, the propensity score was used in regression
(covariance) adjustment [19], i.e., using large set of preoperative
variables as above to estimate the propensity score, and then the
propensity score was subsequently regressed as an independent
covariate in the multivariate logistic regression analysis, which was
performed by using all relevant variables to identify independent
predictors or risk factors for postoperative MACE, renal failure,
and mortality.
Potential preoperative confounding factors considered in this
analysis were selected on the basis of a literature review, clinical
plausibility and variables collected in the database. These variables
included (1) demographic characteristics such as age, gender, and
body mass index (BMI); (2) patient history such as diabetes,
hypertension, peripheral vascular disease, cerebrovascular disease,
chronic lung disease, family History of coronary artery disease
(CAD); (3) preoperative risk factors such as angina, congestive
heart failure, previous MI, multiple CAD, left main CAD, and
preoperative medications such as b-blockers, digitalis, diuretics
and rennin-angiotensin system inhibitors (RAS inhibitors includ-
Figure 1. Selection of study sample.
doi:10.1371/journal.pone.0030094.g001
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sin-II receptor blockers [ARB]) in addition to aspirin and (4)
intraoperative factors including perfusion time and cross-clamp
time.
Models fit analysis was evaluated with the Hosmer-Lemeshow
goodness-of-fit statistic. The C statistic was reported as a measure
of predictive power. Results are reported as percentages and odds
ratios (OR) and with 95% confidence intervals (CI). All reported p
values were 2-sided, and p values,0.05 were considered to be
statistically significant. Statistical analysis was performed with
SPSS 17.0 software for Windows (SPSS Inc., Chicago, IL).
Results
Baseline and intraoperative parameters
Of 1879 patients in the database, 1145 patients met the
inclusion criteria and were divided into two groups: using (n=858)
or not using (n=287) preoperative (within 5 days preceding
surgery) aspirin (Fig. 1). Demographic and clinical data of the
patients who did and did not receive preoperative aspirin therapy
are presented in Table 1. No significant differences were evident
between two groups in body mass index (BMI), medical history
(smoking, cerebrovascular disease, chronic lung disease), clinical
pattern (congestive heart failure, cardiogenic shock), and preop-
erative medical therapy (digitalis, diuretics use). However, the
patients with aspirin presented more with history of hypertension
(84.4% vs. 69.0%, P,0.001), diabetes (35.0% vs. 23.7%,
P,0.001), peripheral vascular disease (11.0% vs. 4.2%,
P,0.001), previous MI (25.9% vs. 14.6%, P,0.001), angina
(28.9% vs. 17.4%, P,0.001) and family history of coronary artery
disease (CAD) (58.3% vs. 43.9%, P,0.001). And the patients with
aspirin also presented more with preoperative using beta-blockers
and rennin-angiotensin system (RAS) inhibitors. Meanwhile, the
procedural characteristics, including perfusion time (120.2656.2
vs. 104.3646.9, P,0.001) and aortic cross-clamp time (95.3649.5
vs. 82.6641.3, P,0.001), were significantly longer in the patients
without aspirin.
Postoperative cardiocerebral and renal complications
and mortality
Among 1145 patients undergoing cardiac surgery, a total of
9.5% of all patients experienced at least one of cardiocerebral
complications, including permanent or transient stroke, coma,
perioperative MI, heart block and cardiac arrest. The incidence of
MACE in patients who received preoperative aspirin was 8.4%
compared with 12.5% for patients who did not receive aspirin
(P=0.035), indicating preoperative use of aspirin significantly
decreased the risk of a composite outcome - cardiocerebral
complications (by 33.3%) in patients undergoing cardiac surgery
(Fig. 2).
Among other complications, compared with no aspirin
preoperatively, preoperative use of aspirin also significantly
reduced the risk of postoperative renal failure (2.6% vs. 5.2%,
P=0.035) and dialysis required (0.8% vs. 3.1%, P=0.014).
Importantly there was no difference in incidence of readmission
(Fig. 2), which was most due to such as pericardial effusion and/or
tamponade, deep stern infection, pneumonia or respiratory
complication, arrhythmia and etc, indicating that an obvious
increase in postoperative bleeding that needs to be admitted did
not occur in patients taking preoperative aspirin.
Overall, the 30-day all cause mortality rate was 50 of 1145
(4.4%). The 30-day mortality was 4.1% for patients with
preoperative aspirin and 5.8% for patients without one
(P=0.396). The 30-day mortality rate was 9.3% (10/107) for
patients with postoperative cardiocerebral events compared with
4.0% (40/988) for patients without postoperative cardiocerebral
events (P=0.013), indicating postoperative cardiocerebral com-
plications significantly contributing to the death associated with
cardiac surgery.
Independent risk factors for MACE
The unadjusted univariate analysis showed that risk factors
related with MACE were age, male sex, diabetes, hypertension,
angina, congestive heart failure, multiple CAD, preoperative
aspirin, diuretics and digitalis therapy, perfusion time and cross-
clamp time (Table 2).
Figure 2 (3 columns on the right) presents the multivariate
analysis to assess independent risk factors for postoperative
complications, including cardiocerebral (MACE) and renal
complications and 30-day all-cause mortality. After adjusting for
propensity score and covariates, preoperative aspirin did not show
a significant effect on readmission (12.6% vs. 14.3%) and 30-days
all cause mortality (4.1% vs. 5.8%), also individual adverse
cardiocerebral events including periopeative MI (1.5% vs. 1.7%),
coma (1.6% vs. 1.4%), heart block (3.4% vs. 5.6%) and cardiac
arrest (1.2% vs. 2.4%).
Using multivariable logistic regression adjusted with propensity
scores, however, patients who took preoperative aspirin compared
Table 1. Demographic and clinical characteristics.
Characteristics Aspirin P value
Yes No
n=858 n=287
Age, yrs 65.3612.0 59.1615.3 ,0.001
Male gender, % 602(70.2) 167(58.2) ,0.001
Body mass index, kg/m2 29.669.3 29.8615.0 0.774
Past medical history
Diabetes 300(35.0) 68(23.7) ,0.001
Hypertension 724(84.4) 198(69.0) ,0.001
Smoker 163(19.0) 63(22.0) 0.276
Cerebrovascular disease 116(13.5) 30(10.5) 0.178
Peripheral vascular disease 94(11.0) 12(4.2) 0.001
Chronic lung disease 256(29.8) 78(27.2) 0.391
Family History CAD 500(58.3) 123(42.9) ,0.001
Clinical pattern
Angina 248(28.9) 50(17.4) ,0.001
Congestive heart failure 104(12.1) 43(15.0) 0.210
Previous MI 222(25.9) 42(14.6) ,0.001
Multiple CAD 661(77.0) 108(37.6) ,0.001
Left main CAD 167(19.5) 18(6.3) ,0.001
Medical therapy
Beta-blockers 662(77.2) 140(48.8) ,0.001
Diuretics 253(29.5) 80(27.9) 0.603
Digitalis 35(4.1) 11(3.8) 0.854
ACE or ARB Inhibitors 357(41.6) 83(28.9) ,0.001
Perfusion time (min) 104.3646.9 120.2656.2 ,0.001
Cross-clamp time (min) 82.6641.3 95.3649.5 ,0.001
Values are n (%) for categorical variables and mean6SD for continuous
variables.
doi:10.1371/journal.pone.0030094.t001
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risk of postoperative MACE, permanent stroke, renal failure and
dialysis required (Fig. 2).
The multivariate model significantly predicted the occurrence of
postoperative cardiocerebral complications (model x
2, 90.48;
P,0.001). The discriminatory ability of the logistic model was
acceptable (C statistic, 0.749; 95% CI, 0.697 to 0.801; P,0.001).
The model was well calibrated among deciles of observed and
expected risk (Hosmer-Lemeshow x
2, 8.60; P=0.38).
Discussion
The major findings from this observational cohort study are that
preoperative use of aspirin is associated with a significant decrease
in the risk of postoperative MACE (8.4% vs. 12.5%), renal failure
(2.6% vs. 5.2%) and dialysis required (0.8% vs. 3.1%), meanwhile
it is not associated with increased risk of readmissions in patients
undergoing non-emergent cardiac surgery. However, preoperative
use of aspirin did not show a significant effect on postoperative
mortality in this sub-group study.
Cardiocerebral events are still common postoperative compli-
cations for patients undergoing cardiac surgery, including stroke
(1.4%–4.6%), cardiac arrest (5.0%), MI (3.1%–9.1%) [1]–[3], [20–
22]. Although there has been lacking of the effective therapy to
prevent these complications, several lines of evidence have
demonstrated the effectiveness of aspirin, as an antiplatelet and
antiinflammatory medicine, in the prevention and treatment of
CVD. First, the Antiplatelet Trialists’ Collaboration, a meta-
analysis, has shown that among the high risk patients for CVD,
aspirin significantly reduced rates of MI, stroke and death [5].
Second, in the setting acute MI and stroke, aspirin therapy
reduced cardiovascular morbidity and mortality, including
recurrent ischemic stroke [23] and myocardial reinfarction [24].
Third, the antiplatelet therapy with aspirin and clopidogrel (plavix)
has been recommended to be started before and continuously in
percutaneous coronary intervention [25].
In the setting of cardiac surgery, in 2002, Mangano et al [8] in a
prospective multicenter study (n=5065) showed that among
patients who received aspirin within 48 hours after revasculariza-
tion (CABG), subsequent mortality was 1.3%, as compared with
4.0% among those who did not receive aspirin during this period
(OR 0.41, 95% CI 0.27–0.62, P,0.001). In addition, aspirin
therapy was associated with a 48% reduction in the incidence of
MI (2.8% vs. 5.4%, P,0.001), a 50% reduction in the incidence of
stroke (1.3% vs. 2.6%, P=0.01), a 74% reduction in the incidence
of renal failure (0.9% vs. 3.4%, P,0.001), and a 62% reduction in
the incidence of bowel infarction (0.3% vs. 0.8%, P=0.01). The
risk of hemorrhage, gastritis, infection, or impaired wound healing
was not increased with aspirin use (OR for these adverse events,
0.63; 95% CI 0.54 to 0.74).
Although the strong evidence supporting aspirin treatment in
the non-surgical setting and even in the surgical setting, such as
immediate postoperative use of aspirin in patients undergoing
CABG as described above [8], preoperative use of aspirin is still
controversial. A major concern of preoperative use of aspirin is its
increasing risk of bleeding and transfusion [10], [15]. As a matter
of fact, AHA/ACC [26] the Society of Thoracic Surgeons (STS)
[27] and the European Association for Cardio-Thoracic Surgery
[28] recommended that patients should stop aspirin several days
(ranged from 2–10 days) before elective cardiac surgery, mainly
due to concerns of perioperative bleeding.
With these controversies, in 2005, Bybee et al [29] performed a
retrospective study on preoperative aspirin therapy and postoper-
ative outcomes in patients (n=1636) undergoing first-time isolated
CABG at a single institution. Major findings of this study are 1)
preoperative aspirin significantly lowered postoperative in-hospital
mortality compared with those not receiving preoperative aspirin
(1.7% vs. 4.4%, adjusted OR 0.34, 95% CI 0.15–0.75, P=0.007).
2) Rates of postoperative cerebrovascular events including cerebral
vascular accident or transient ischemic attack were similar
between groups (2.7% vs. 3.8%, adjusted OR 0.67, 95% CI
Figure 2. Effects of aspirin on postoperative complications and mortality in patients undergoing cardiac surgery. Values are n (%) for
categorical variables and mean6SD for continuous variables. OR, odd ratio; CI, confidence interval; MACE, major adverse cardiocerebral events; MI,
myocardial infarction; TIA, transient ischemic attack.
doi:10.1371/journal.pone.0030094.g002
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associated with an increased risk of reoperation for bleeding (3.5%
vs. 3.4%, P=0.96) or requirement for postoperative blood product
transfusion (adjusted OR, 1.17, 95% CI, 0.88–1.54, P=0.28).
Recently, Jacob et al [30] reported in an observational single
institution study that among patients undergoing non-emergent
isolated CABG, late (within 5 days of the surgery) use of aspirin (vs.
discontinued aspirin $6 days before surgery) was associated with
no significant difference in a composite outcome of in-hospital
mortality, MI and stroke (1.8% vs. 1.7%, P=0.80) and
reoperations for bleeding (3.4% vs. 2.4%, P=0.10) but more
intraoperative transfusions (23% vs. 20%, P=0.03) and postop-
erative transfusions (30% vs. 26%, P=0.009). Although the study
of Jacob et al showed that preoperative aspirin was associated with
a small increase in transfusion requirements (23% vs. 20%), the
patients with preoperative aspirin use (vs. nonaspirin) were
associated with increased anticoagulant use (49% vs. 30%,
P,0.0001), which may cause/contribute to the increase in
transfusion requirements.
Compared with these earlier studies, this study showed that
preoperative use of aspirin was associated with a decrease of a
composite outcome - MACE by 33% in patients undergoing
cardiac surgery; it was also associated with reduced the risk of
postoperative renal failure and dialysis required. The renal
protective effect by aspirin was unexpected when starting this
study, though a previous report also showed that preoperative
aspirin had beneficial effects on renal function in patients with
renal insufficiency undergoing CABG [31]. Potential mecha-
nism(s) for this renoprotection remains to be investigated and
probably are more related to anti-inflammatory (than anti-platelet)
effects of aspirin in the setting of cardiac surgery.
The present study did show a trend to decrease the death (4.1%
vs. 5.8%; OR 0.744, 95% CI 0.376–1.472 P=0.396). The authors
recognized, however, that a sample size larger than the present
one would be needed to determine the effect of aspirin on
postoperative mortality (to detect a statistical difference), which has
been demonstrated in our recent study [32]. Noticeably, the
patients with preoperative aspirin were older and sicker, such as
more with history of hypertension, diabetes, peripheral vascular
disease, previous MI, angina, left main and multiple CAD (as seen
in Table 1). Nevertheless, this study provided additional evidence
(to a recent study [32]) that aspirin protects the heart, brain and
kidneys against those major risk factors in a sub-group (non-
emergent) of patients, indicating its efficacy and potential
application to these high-risk patients.
Limitations of this study. This is an observational cohort study.
Although multivariate regression in combination with the
propensity score adjustment was used in this study to reduce
overt biases, the potential flaws of a non-randomized study may
remain. Second, this is a separate and sub-group study on
preoperative aspirin and cardiac surgery, which excluded the
patients undergoing emergent cardiac surgery; multicenter, larger
(than the present one in the sample size) and cohort studies are
needed to investigate this subject step-by-step, as showed in our
recent study [32]. Third, cardiac surgery patients share the
common risk of postoperative complications involving the brain,
heart and kidneys, despite of undergoing different cardiac
surgeries. While aspirin, mainly through its antiinflammatory
and antithrombotic effects, may break common final pathways
responsible for these complications. Thus, although this study
provided an overall analysis on effects of preoperative aspirin on
outcomes in patients undergoing cardiac surgery (mainly CABG
and/or valve surgery), further studies to dissect different types of
cardiac surgery (CABG, valve, emergent or elective alone or/and
combinations) are needed and probably would provide more detail
information about aspirin and cardiac surgery. As indicated
before, nonetheless, ‘‘the overall result of the clinical study (trial) is
usually a better guide to the direction of effect in subgroups than
the apparent effect observed from the individual subgroups’’ [33].
Finally, this study did not provide detailed information about
perioperative bleeding, and further studies are still needed to
examine this potential side effect carefully (on a case by case base).
In conclusion, the results of this study showed that preoperative
use of aspirin is associated with a significant decrease in the risk of
MACE and renal complications in patients undergoing non-
emergent cardiac surgery; these beneficial effects were not
associated with increased risk of readmissions. Further clinical
studies including randomized or (large) observational studies are
needed to elucidate the role of preoperative aspirin in cardiac
surgery.
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Table 2. Univariate Logistic Regression Analysis for Risk
Factor Associated with Postoperative Cardiocerebral Events.
Characteristics Cardiocerebral Events P value
Yes No
n=108 n=1037
Age, yrs 61.4614.1 64.0613.0 0.043
Male gender, % 84(72.5) 685(66.1) 0.014
Body mass index, kg/m2 29.067.6 29.7611.3 0.510
Past medical history
Diabetes 46(42.6) 322(31.1) 0.015
Hypertension 96(88.9) 826(79.7) 0.021
Smoker 27(25.0) 199(19.2) 0.149
Cerebrovascular disease 12(11.1) 134(12.9) 0.591
Peripheral vascular disease 11(10.2) 95(9.2) 0.727
Chronic lung disease 27(25.0) 307(29.6) 0.316
Family History CAD 50(46.3) 573(55.3) 0.075
Clinical pattern
Angina 38(35.2) 260(25.1) 0.023
Congestive heart failure 43(39.8) 104(10.0) ,0.001
Previous MI 31(28.7) 233(22.5) 0.143
Multiple CAD 61(56.5) 708(68.3) 0.013
Left main CAD 22(20.4) 163(15.7) 0.211
Medical therapy
Beta-blockers 82(75.9) 720(69.4) 0.161
Diuretics 49(45.4) 284(27.4) ,0.001
Digitalis 9(8.3) 37(3.6) 0.016
ACE or ARB Inhibitors 47(43.5) 393(37.9) 0.253
Aspirin 72(66.7) 786(75.8) 0.037
Perfusion time (min) 131.4671.3 105.8646.3 ,0.001
Cross-clamp time (min) 103.2661.1 84.0641.2 ,0.001
Values are n (%) for categorical variables and mean6SD for continuous
variables.
doi:10.1371/journal.pone.0030094.t002
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